Natera (NTRA) Morgan Stanley 24th Annual Global Healthcare Conference summary

Business performance and growth outlook

• Achieved nearly 40% year-over-year sales growth in Q2, with record sequential Signatera test volumes and multiple revenue raises.

• MRD market opportunity is considered vast and underappreciated, with strong growth expected to continue for an extended period.

• Adoption of MRD testing has reached a tipping point, with physicians now focused on implementation rather than validation.

• FDA approval and NCCN guidelines for MRD have accelerated clinical adoption and are expected to drive further volume growth.

• Biopharma partnerships are expanding rapidly, with MRD-guided strategies becoming central to new phase III clinical trials.

Product innovation and competitive positioning

• Ongoing investment in peer-reviewed evidence and multiple upcoming clinical readouts across various cancer types through 2027.

• Expanded MRD offerings include exome, genome-based, and tumor-naive products, providing comprehensive solutions for physicians.

• Recent launches in women's health, such as Fetal Focus and improved NIPT with lower no-call rates, have driven strong uptake.

• Competitive moat is reinforced by clinical data, EMR connectivity, patient base, and technological advancements.

• AI initiatives target operational efficiency, enhanced user experience, and product innovation, with significant OpEx savings anticipated.

Financial strategy and investment priorities

• Average selling price (ASP) for Signatera is expected to rise from $1,275 to $2,000, driven by expanded coverage and guideline inclusion.

• Japan launch is anticipated to see rapid uptake due to strong academic engagement and prior clinical trial participation.

• Company remains in reinvestment mode, prioritizing high-ROIC projects and innovation over near-term EBITDA.

• R&D spend is heavily focused on long-term growth, with major investments in early cancer detection (ECD) and colorectal cancer screening.

• M&A is approached selectively, with a primary focus on internal R&D and targeted acquisitions to fill portfolio gaps.